10/12/2025
🎄 Secure your ticket before the holiday break!
The 2nd Pre-Approval Access to Medicines in Asia-Pacific Conference returns on 10–11 March 2026 in Singapore.
🔗 https://eu1.hubs.ly/H0qj9By0
The Asia-Pacific region is home to over 60% of the world’s population, yet hosts only 15–20% of global clinical trials and even fewer expanded access programs. Fragmented regulations, operational complexity, and resource constraints continue to limit timely pre-approval access for patients across APAC.
💡Last year’s inaugural conference created a long-awaited forum for industry, regulators, clinicians, and patient advocates to tackle these gaps together. As one participant shared:
“It was an extremely valuable conference. The patient group representatives added greatly to the discussion, which hasn’t always been the case at conferences.”
In 2026, we build on that momentum with a sharper focus on scalable, sustainable approaches for early access across APAC.
Key themes include
✔️Establish ethical principles to guide sustainable pre-approval access across APAC.
✔️Leverage pre-approval access as a strategic entry point for long-term APAC access.
✔️Assess regulatory maturity to enable scalable, sustainable access solutions.
✔️Strategies to reduce time-to-launch for medicines in APAC markets.
✔️Operational success factors for launching and scaling access programs.
If you work in biopharma, regulation, healthcare, research, or patient advocacy, this conference offers a unique opportunity to collaborate on overcoming regional barriers and accelerating patient access across the APAC region
🌏 Co-hosted by Novartis, Roche, BeOne Medicines, and the Asia Pacific Alliance of Rare Disease Organisations (APARDO), the 2026 edition brings together industry, clinical, and patient advocacy perspectives to move discussions beyond theory and into practical, region-ready solutions.
👉 Register here: https://eu1.hubs.ly/H0qj9By0